RIPK3 and pulmonary emphysema: Moreover, inhibition of RIP3 by GSK’872 attenuated inflammation and subsequent emphysema in mice exposed to 6 months’ smoking, indicating that targeting the necroptosis signaling pathway might be a potential therapeutic strategy for patients with COPD (Figure 7).